Given that Fz2 was found selectively elevated in the brain of patients with FTD and Fz2 activates a non-canonical Wnt pathway it is suggested that modulation of this pathway could be therapeutically beneficial for this demential illness. The gene discussed is FZD2; the disease is frontotemporal dementia.